The emergence of adamantane resistance in influenza A(H1) viruses in Australia and regionally in 2006
The emergence of adamantane resistance in influenza A(H1) viruses in Australia and regionally in 2006
复制标题
DOI：
10.1016/j.antiviral.2007.01.006
复制
发表时间：
2007-08-01
影响因子：
7.6
通讯作者：
Komadina, N.
中科院分区：
文献类型：
--
作者：
Barr, I. G.;Hurt, A. C.;Komadina, N.
金刚烷（金刚烷胺和金刚乙胺）是第一批获准用于对抗甲型流感病毒的抗病毒药物，并已在一些国家用于控制季节性流感。虽然近年来报告了A（H3）病毒对这类药物的耐药性增加，但直到2005-2006年美国流感季节，A（H1）病毒的耐药性水平才很低。在这项研究中，我们分析了2006年从澳大利亚和周边地区分离到的101株人甲型流感病毒，这些病毒被提交给位于墨尔本的世卫组织参考和研究合作中心，以获得对金刚烷耐药的证据。我们发现，虽然以前的A（H1）耐药病毒是罕见的，21.8%的2006年病毒具有耐药基因型。相比之下，2006年在该中心检测的甲型H3流感病毒中有58.6%具有耐药基因型。(C)2007 Elsevier B. V.保留所有权利。
The adamantanes (amantadine and rimantadine) were the first antivirals licensed for use against influenza A viruses and have been used in some countries to control seasonal influenza. While increasing resistance of A(H3) viruses to this class of drug has been reported in recent years, only low levels of resistance were seen with A(H1) viruses until the 2005-2006 influenza season in the USA. In this study we analysed 101 human influenza A viruses isolated in 2006 that were referred to the WHO Collaborating Centre for Reference and Research in Melbourne, from Australia and the surrounding regions, for evidence of resistance to adamantanes. We found that whereas previously A(H1) resistant viruses were rare, 21.8% of the 2006 viruses had a resistant genotype. By comparison, 58.6% of influenza A(H3) viruses isolated in 2006 that were tested at the Centre, had a resistant genotype. (C) 2007 Elsevier B.V. All rights reserved.